News

A new therapy which is administered directly into the lung of viruses can kill bacteria, and was shown to be effective in reducing Pseudomonas aeruginosa infection and associated inflammation in a mouse model of cystic fibrosis (CF). This new strategy may pave the way for future treatments of…

Cystic fibrosis (CF) patients have a higher amount of harmful gut bacteria and increased levels of intestinal inflammation than healthy people, according to researchers. Their study, “Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis,” was published in the…

A natural component found in cinnamon oil, known as cinnamaldehyde or CAD, may be able to prevent Pseudomonas aeruginosa bacteria from spreading in an organism and inhibit their ability to form antibiotic-resistant biofilms, researchers show. These findings may support further study into anti-microbial medications that can help control the behavior of…

An earlier diagnosis and treatment of nontuberculous mycobacteria (NTM) infection in patients with cystic fibrosis (CF) may positively affect the patient’s lung function, a study suggests. NTM are a group of bacterial species, found in soil and water, which are not usually associated with human disease, except if they infect…

The adaptation of bacteria Pseudomonas aeruginosa to the lungs of cystic fibrosis (CF) patients may make them more susceptible to antibiotics and easier to kill, according to new research. The study with that finding, “Evolutionary trade-offs associated with loss of PmrB function in host-adapted Pseudomonas aeruginosa,”…

Treating cystic fibrosis (CF) patients with the antibiotic azithromycin in addition to vitamin E supplements did not change their oxidative stress status in a pilot study, researchers report. These results were published in the journal Frontiers in Pharmacology, in the article “Metabolomic Analysis by Nuclear Magnetic Resonance…

Adding azithromycin to the standard antibiotic treatment for early Pseudomonas aeruginosa infections is associated with fewer pulmonary exacerbations in children with cystic fibrosis (CF), results from a Phase 3 trial show. Trial findings were published in the study, “Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis: The Optimize Randomized…

The Mike McMorris Cystic Fibrosis Research and Care Center, part of the Children’s Hospital Colorado, is one of the 82 clinical sites involved in the Phase 3 clinical trial that is assessing the efficacy of VX-659 in a triple combination with Symdeko (tezacaftor/ivacaftor and ivacaftor). The…

Adding GLPG2737, Galapagos’ investigational CFTR corrector, to Vertex’s Orkambi (lumacaftor/ivacaftor) enhances the effectiveness of the treatment in cystic fibrosis patients with two copies of the F508del mutation, topline results from a Phase 2 trial show. Conducted at multiple sites in Germany, the Phase 2 PELICAN clinical…

Taking a marine-origin omega-3 compound, docosahexaenoic acid monoglyceride (MAG-DHA), can improve the absorption of fats and reduce inflammation in patients with cystic fibrosis (CF). The study with that finding, “The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients,” was published in the journal…